Open access
Open access
Powered by Google Translator Translator

Phase 2 trial of Oxford COVID-19 vaccine finds it is safe and provokes immune response in young as well as in older adults

20 Nov, 2020 | 08:50h | UTC

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Commentaries: Covid: Oxford vaccine shows ‘encouraging’ immune response in older adults – BBC AND Age and frailty in COVID-19 vaccine development – The Lancet AND Expert reaction to phase 2 trial safety and immunogenicity data from the Oxford COVID-19 vaccine trial including in healthy older adults – Science Media Centre AND Phase 2 trial of Oxford COVID-19 vaccine in healthy older adults finds it is safe and provokes immune response – The Lancet

 

Commentary on Twitter

 


Stay Updated in Your Specialty

 

No spam, just news.